LifeVantage Corporation (LFVN)

Market Cap	78.42M -41.5%
Revenue (ttm)	182.59M -20.1%
Net Income	5.07M -48.3%
EPS	0.40 -46.7%
Shares Out	12.53M
PE Ratio	15.65
Forward PE	19.36
Dividend	$0.20 (3.20%)
Ex-Dividend Date	Sep 1, 2026

Volume	10,349
Open	6.29
Previous Close	6.29
Day's Range	6.25 - 6.42
52-Week Range	3.90 - 11.71
Beta	0.76
Analysts	Buy
Price Target	7.50 (+19.81%)
Est. Earnings	Nov 3, 2026

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye a...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Terrence Moorehead
• Employees: 223
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In fiscal year 2026, LifeVantage's revenue was $182.59 million, a decrease of -20.10% compared to the previous year's $228.53 million. Earnings were $5.07 million, a decrease of -48.27%.

Analyst Summary

According to 2 analysts, the average rating for LFVN stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 19.81% from the latest price.

Price Target

$7.5

(19.81% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 26, 2026

Data Sources Report a data error